TBNHealth
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Publication: STAT
Author: Ed Silverman
Source published: 10/11/2026, 13:38:35 UTC
Briefing created: 11/11/2026, 04:54:22 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 15:06:24 UTC.
Briefings
Dutch regulators are investigating Biogen for potentially abusing its dominant market position in multiple sclerosis treatments. The probe focuses on Biogen's exclusive test for patients on Tysabri, a drug that must be tested for fatal or disabling risks, while refusing to provide the same test to patients on rival biosimilar Tyruko. This investigation centers on whether Biogen reserved the test exclusively for its own product, potentially creating an unfair barrier to entry for competitors.
Key points
- Dutch regulators are investigating Biogen for potentially abusing its dominant market position in multiple sclerosis treatments.
- Biogen developed a test for the virus causing progressive multifocal leukoencephalopathy and provides it free of charge exclusively to patients receiving Tysabri.
Context
The Netherlands Authority for Consumers and Markets (ACM) is probing whether Biogen reserved a test for patients on Tysabri while refusing to make the test available to patients on rival medications like Tyruko. This probe centers on whether Biogen abused its dominant position in the market for multiple sclerosis treatments and associated blood tests.
Limitations
Evidence is limited to the Dutch regulator's investigation into Biogen's test exclusivity for Tysabri patients versus Tyruko patients. No specific dates, numbers, or names of other companies are provided beyond the Dutch regulator and the two drug names. The investigation status is ongoing and no final findings or outcomes are reported in the source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 11/11/2026, 04:54:22 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidfssu764agx44l2etftzii6w4dii2ydlevnh24duwrhwwhrbzemm